Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Glofitamab, IV Glofitamab
Glofitamab+ Obinutuzumab · 1 trial · 1 indication
Percentage of patients with a complete response (CR) assessed using the Cheson IWG 2014 Lugano Classification (i.e. Deauville scale 1-3)
| Arm | Type | Description |
|---|---|---|
| Glofitamab + Obinutuzumab | EXPERIMENTAL | cf Intervention |
| Name | Type | Description |
|---|---|---|
| Glofitamab + Obinutuzumab | DRUG | Duration of each cycle is 21 days. Cycle 1: R-CHOP Cycle 2: G-CHOP + glofitamab (at this cycle onnly, Obinutuzumab will be injected instead of Rituximab in order to decreased the risk of cytokine released syndrome) Cycle 3-6: R-CHOP + glofitamab Cycle 7-8: glofitamab alone |
Inclusion Criteria: 1. Confirmed diagnosis of chronic lymphocytic leukemia or small lymphocytic lymphoma according to the revised iwCLL criteria with biopsy proven transformation to CD20 positive diffuse large B-cell lymphoma, consistent with RS according to the 2016 WHO classification 2. A fresh o...
Glofitamab is an investigational bispecific antibody being studied for the treatment of B-cell lymphomas, including non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), and Richter syndrome. It is being evaluated in combination with other agents such as rituximab, obinutuzumab, and polatuzumab vedotin in clinical trials.
Glofitamab is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with various B-cell malignancies.
Glofitamab is in Phase 1 and Phase 2 clinical trials. It is an investigational agent and has not been approved by regulatory authorities. Studies are ongoing to assess its safety and efficacy in treating B-cell lymphomas.
Glofitamab is being studied in several trials, including NCT03467373, a Phase 1 study in non-Hodgkin lymphoma and DLBCL; NCT03533283, a Phase 1b/II study in relapsed/refractory B-cell non-Hodgkin's lymphoma; NCT04313608, a Phase 1 study in DLBCL; and NCT06765317, a Phase 2 study in DLBCL.
Glofitamab is also known as IV Glofitamab, and it is studied in combination with obinutuzumab, referred to as Glofitamab + Obinutuzumab. These names refer to the same investigational drug, which is being evaluated alone or with other therapies.
Glofitamab is a bispecific antibody, a type of -mab (monoclonal antibody) therapy. It is designed to engage T-cells to target and destroy B-cells that express specific antigens, which is relevant in B-cell malignancies. Its mechanism involves bridging immune effector cells to tumor cells.